Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients
Objective: to assess clinical and economic implications of adding daratumumab (Dara) to the "lenalidomide + dexamethasone" (Rd) treatment program in early lines of therapy for patients with multiple myeloma (MM) ineligible for high-dose chemotherapy (HDCT) with subsequent autologous hemato...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
IRBIS LLC,
2024-05-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|